BB Biotech AG publishes its 2024 annual report

Ad hoc announcement pursuant to Art. 53 LR

February 21, 2025

Annual report of BB Biotech AG as at December 31, 2024 

BB Biotech AG publishes its 2024 annual report

BB Biotech AG published its annual report for fiscal year 2024 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech’s positioning, the investment areas covered by its portfolio and the companies it is invested in.

In 2024, BB Biotech AG shares delivered a total return of -13.5% in CHF and -14.1% in EUR, including the CHF 2.00 dividend paid in March 2024. Our Net Asset Value (NAV) performance showed greater resilience, increasing by 3.0% in CHF and 1.7% in EUR for the year, while declining by 4.6% in USD. For the full year 2024, BB Biotech AG recorded a net profit of CHF 76 mn compared to a net loss of CHF 207 mn in 2023.

As already announced on January 24, 2025, BB Biotech AG will propose a dividend of CHF 1.80 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech AG shares in December 2024. This marks a continuation of the dividend policy of the previous years.

BB Biotech’s annual report 2024 is available under report.bbbiotech.ch/2024/en resp. www.bbbiotech.com

For further information:

Bellevue Asset Management AG, Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00

Head Investment Management Team BB Biotech
Dr. Christian Koch

Investor Relations
ir@bbbiotech.com
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch
Maria-Grazia Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

Media Relations
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile  
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.